Introduction
============

Fuchs uveitis syndrome (FUS) is a chronic unilateral ocular inflammatory disease which mainly affects young adults. It is a relatively common uveitis entity in China and is characterized by medium-sized or stellate keratic precipitates, a variable degree of iris depigmentation or heterochromia without posterior synechiae \[[@r1]\]. Although the etiology of FUS has not yet been fully elucidated \[[@r2]\], both environmental and genetic risk factors have been suggested to be involved in its pathogenesis. Several groups have identified an association with rubella infection and FUS \[[@r3]\] and a decline has been noted in the incidence which is ascribed to vaccination programs against rubella. Earlier studies showed an association of the human leukocyte antigen-B18 (*HLA-B18*) with FUS \[[@r4]\]. Furthermore, recent studies have addressed the association of polymorphisms of the intercellular adhesion molecule 1 (*ICAM-1*) gene \[[@r5]\], the cytotoxic T cell antigen (*CTLA*) *4* gene \[[@r6]\], and the interleukin 23 receptor (*IL23R*) gene \[[@r7]\] with this disease.

The cluster of differentiation 40 (*CD40*) gene is located on chromosome 20q13 and encodes the CD40 protein, which plays an important role in the onset and severity of multiple inflammatory autoimmune diseases and the initiation and maintenance of inflammation triggered by infections through interaction with its ligand (cluster of differentiation 154 \[CD154\]) \[[@r8]\]. Recently, genome-wide association surveys have identified the association at the *CD40* locus with rheumatoid arthritis \[[@r8]\] and multiple sclerosis \[[@r9]\]. Multiple candidate gene studies have also identified and validated the association of several SNPs in *CD40* with autoimmune or autoinflammatory diseases including Graves' disease \[[@r10]\], Crohn\'s disease, multiple sclerosis \[[@r11]\], and rheumatoid arthritis \[[@r12]\]. As CD40-CD40L binding is required in the priming of cluster of differentiation 8^+^ (CD8^+^) T cell following virus infection, the *CD40* polymorphism might influence the cytotoxic T cell responses in the virus infection associated diseases, such as FUS which has been reported to be associated with rubella and CMV infection. Therefore, we investigated the association of [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) and [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) at the *CD40* locus with FUS. Unfortunately, we failed to find any association of its polymorphisms with this disease in a Han Chinese population.

Methods
=======

Patients and healthy controls
-----------------------------

A total of 131 Han Chinese patients with FUS and 402 age-, sex-, and ethnic-matched healthy controls were consecutively recruited from the Uveitis Study Center of the Sun Yat-sen University (Guangzhou, P.R. China) and the First Affiliated Hospital of Chongqing Medical University (Chongqing, P.R. China). The diagnosis of FUS was made according to the clinical manifestations as described earlier \[[@r1]\] Briefly, the clinical manifestations include low-grade anterior chamber response, characteristic medium-sized or stellate keratic precipitates, and diffuse iris depigmentation or heterochromia without posterior synechiae. The Ethics Committees of the First Affiliated Hospital of Chongqing Medical University approved the study. The tenets of the Declaration of Helsinki were conducted during all procedures of this present study. The donors were enrolled in the study after informed consent.

Genomic DNA extraction and genotyping
-------------------------------------

Blood samples were collected in EDTA tubes and kept at −70 °C until use. Genomic DNA was isolated using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA ). The primers of the *CD40* gene polymorphisms listed in [Table 1](#t1){ref-type="table"} were used to amplify the target DNA by the polymerase chain reaction (PCR). Each PCR reaction was conducted in 10 μl containing 5 μl Premix Taq (Ex Taq Version; TaKaRa Biotechnology Co. Ltd., Dalian, China), 20 pmol primers, and 0.2 μg of genomic DNA for amplification of the DNA. The conditions were as follows: initial denaturation at 95 °C for 5 min followed by 38 cycles of denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s, extension at 72 °C for 25 s, and a final extension at 72 °C for 5 min. The two tested SNPs were genotyped by PCR-restriction fragment length polymorphism (RFLP) analysis. PCR products of the [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) and [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) polymorphisms were respectively digested with 4 U of MspI (Fermentas International Inc., Burlington, Canada) and NcoI (Fermentas International Inc.; [Table 1](#t1){ref-type="table"}) in a 10 μl reaction volume overnight. The amplified PCR products were electrophoresed on a 3.5% agarose gel and stained with GoldView™ (SBS Genetech, Beijing, China). The results were validated by direct sequencing by the Majorbio Bio-Pharm Technology Company (Shanghai, China) in 10% of the total samples.

###### Primers of CD40 SNPs and restriction enzymes for RFLP analysis

  **Rs number**                                                 **Primers**                     **Restriction enzyme**
  ------------------------------------------------------------- ------------------------------- ------------------------
  [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485)   5′-TATTTTTGTAGTTCCTCATTCTG-3′   MspI
  ** **                                                         5′-GCCCCCCTTTACCTCTTTC-3′       ** **
  [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832)   5′-CCCCGATAGGTGGACCGCGATTG-3′   NcoI
  ** **                                                         5′-CCCGCCCTCTGAACCCCCTACCA-3′   ** **

RFLP, restriction fragment length polymorphism.

Statistical analysis
--------------------

Hardy--Weinberg equilibrium (HWE) was evaluated in the subjects using the chi-square test. Genotype frequencies were obtained by direct counting. The statistical analysis was performed using the χ^2^ test with SPSS (version 17.0; SPSS Inc., Chicago, IL) to compare the genotype and allele frequencies between patients and controls. We used Bonferroni correction to account for multiple testing. The statistical significance was set at pc\<0.05.

Results
=======

One hundred and thirty-one consecutive Han Chinese patients with FUS were enrolled in the present study (72 males and 59 females). The average age of the patients with FUS in the present study was 38.2±10.1 years (age range 16--68 years). The healthy controls consisted of 402 subjects (241 males and 161 females), in which the average age was 37.2±10.6 years (age range 12--72 years). The age and gender distribution of the patients with FUS and controls are summarized in [Table 2](#t2){ref-type="table"}.

###### Age and gender distribution in Fuchs' patients and controls.

  ** **            **Patients with FUS**   **Healthy controls**               
  ---------------- ----------------------- ---------------------- ----------- -------
  Age (mean ±SD)   38.2±10.1               ** **                  37.2±10.6   ** **
  Range            16--68                  ** **                  12--72      ** **
  **Sex**                                                                     
  Male             72                      55                     241         60
  Female           59                      45                     161         40

FUS: Fuchs uveitis syndrome.

Two single-nucleotide polymorphisms (SNPs) of *CD40* ([rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) and [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832)) were successfully genotyped in 131 patients with FUS and 402 healthy controls. The results showed that the distribution of genotypes and alleles in subjects were in HWE. The distribution of genotypic and allelic frequencies of the tested two *CD40* polymorphisms is presented in [Table 3](#t3){ref-type="table"}. A trend of increased frequency of genotype of [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) TT and [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) TT was observed in the Fuchs' patient cohort as compared with controls. However there was no statistically significant difference concerning the genotype and allele of both [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) and [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) SNPs between Fuchs' patients and controls. In addition, we failed to find any association of the tested gene polymorphisms with FUS by stratification analysis according to gender.

###### Allelic and genotypic distribution of *CD40* polymorphisms in Fuchs' patients and controls.

  **SNP**                                                       **Genotype allele**   **Fuchs' patients (n=131)**   **Controls (n=402)**   **χ^2^**   **p value**   **Pc**   **OR (95% CI)**
  ------------------------------------------------------------- --------------------- ----------------------------- ---------------------- ---------- ------------- -------- -------------------
  [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485)   TT                    27 (20.6%)                    60 (14.9%)             2.338      0.126         NS       1.48 (0.89--2.45)
  ** **                                                         GT                    59 (45.0%)                    197 (49.0%)            0.623      0.43          NS       0.85 (0.57--1.27)
  ** **                                                         GG                    45 (34.4%)                    145 (36.1%)            0.127      0.721         NS       0.93 (0.61--1.40)
  ** **                                                         T                     113 (43.1%)                   317 (39.4%)            1.125      0.28          NS       1.10 (0.92--1.33)
  ** **                                                         G                     149 (56.9%)                   487 (60.6%)            1.125      0.28          NS       0.29 (0.75--1.09)
  [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832)   TT                    26 (19.8%)                    67 (16.7%)             0.296      0.586         NS       0.87 (0.52--1.44)
  ** **                                                         CT                    61 (46.6%)                    193 (48.0%)            0.083      0.774         NS       0.94 (0.64--1.40)
  ** **                                                         CC                    44 (33.6%)                    142 (35.3%)            0.131      0.717         NS       0.93 (0.61--1.40)
  ** **                                                         T                     113 (43.1%)                   327 (40.7%)            0.493      0.482         NS       1.11 (0.83--1.47)
  ** **                                                         C                     149 (57.5%)                   477 (59.3%)            0.493      0.482         NS       0.90 (0.68--1.20)

Pc Bonferroni corrected p value. NS=Not significant. OR=odds ratio. 95% CI=95% confidence interval.

Discussion
==========

No association was found between the [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) and [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) polymorphisms of *CD40* with FUS in a Han Chinese population.

CD40 is a T cell membrane protein which is critical for CD8^+^ T cell differentiation and the CD8^+^ T cell-mediated response \[[@r13]-[@r15]\]. CD40 is expressed on antigen-presenting cells (APCs) such as macrophages and B cells. CD40 stimulation contributes to APC activation and is required for the priming of CD8^+^ cytotoxic T cell (CTL) and CD4-cell dependent CTL responses to some viruses through interaction with CD154. The interaction of CD40 and CD154 have been shown to play a role in various diseases such as autoimmune thyroiditis, type 1 diabetes, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus \[[@r16]\]. Earlier studies have shown that CD8^+^ T cells are predominant cells in the aqueous humor in patients with FUS \[[@r17]\], suggesting a possible involvement of CD40 in the pathogenesis of this disease.

As there are many SNPs in a candidate gene and only few SNPs may contribute to the disease, it is very important to determine how many and which SNPs should be selected as optimal candidates within the gene to test an association with disease. In the present study, we chose [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) and [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) as the tested SNPs because these were also used in earlier studies \[[@r8],[@r11]\]. [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) was shown to be associated with rheumatoid arthritis risk in Caucasians \[[@r8]\], but not in patients with a Korean ancestry \[[@r18]\]. Our findings showing that [rs4810485](http://www.ncbi.nlm.nih.gov/snp?term=rs4810485) was not associated with FUS could therefore also be due to the ethnic background of our patients.

We also investigated [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832), whereby the common variant increases the efficiency of CD40 translation and which has been associated with Graves' disease \[[@r19],[@r20]\], multiple sclerosis, and Crohn's disease \[[@r12]\]. Of interest is the observation that the minor allele [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) T is protective in Graves' disease but enhances risk of disease in Crohn's disease and multiple sclerosis \[[@r12]\]. We were not able to demonstrate an association between [rs1883832](http://www.ncbi.nlm.nih.gov/snp?term=rs1883832) polymorphisms and FUS.

Associations between CD40 polymorphisms have mainly been shown in autoimmune diseases and the absence of an association with FUS may be due to its infectious etiology \[[@r16],[@r21]\]. Recent studies have for instance detected rubella virus in the anterior chamber and have shown an increased intraocular rubella antibody production in these patients \[[@r22]\].

Since association studies may be influenced by numerous factors, the following measures were used to validate the results. The healthy controls and patients were strictly age-, sex-, and ethnically matched. To validate the result of genotyping by PCR-RFLP, 10% of samples were directly sequenced.

It is worthwhile to point out that there are some limitations in the present study. The sample of the patients was relatively small and only Han Chinese cohorts were included. Therefore, our study is relatively under-powered to examine an association with Fuchs' patients. Larger sample size is needed to detect the association of *CD40* with this disease. Although we failed to find any association between FUS and the investigated two SNPs which have been shown to be associated with several diseases, our result does not rule out the possibility that other SNPs of *CD40* are associated with this disease. Therefore, study is needed to clarify the association of other SNPs of *CD40* with this disease.
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